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Abstract
Necroptosis is a form of regulated cell death caused by formation of the necrosome complex. However, the factors
modulating this process and the systemic pathophysiological effects of necroptosis are yet to be understood. Here, we
identified that Beclin 1 functions as an anti-necroptosis factor by being recruited into the necrosome complex upon treatment
with TNFα, Smac mimetic, and pan-caspase inhibitor and by repressing MLKL oligomerisation, thus preventing the
disruption of the plasma membrane. Cells ablated or knocked-out for Beclin 1 become sensitised to necroptosis in an
autophagy-independent manner without affecting the necrosome formation itself. Interestingly, the recruitment of Beclin 1
into the necrosome complex is dependent on the activation and phosphorylation of MLKL. Biochemically, the coiled-coil
domain (CCD) of Beclin 1 binds to the CCD of MLKL, which restrains the oligomerisation of phosphorylated MLKL.
Finally, Beclin 1 depletion was found to promote necroptosis in leukaemia cells and enhance regression of xenografted-
tumour upon treatment with Smac mimetics and caspase inhibitors. These results suggest that Beclin 1 functions as a
negative regulator in the execution of necroptosis by suppressing MLKL oligomerisation.
Introduction
Necroptosis is a programmed cell death mechanism, initi-
ated by various cytokine, death receptors and pattern
recognizing receptors (PRR) when caspase-8 is inhibited by
pharmacological treatment or genetic modification [1]. The
binding of the respective ligand induces the recruitment of
RIPK Homotypic Interaction Motif (RHIM) containing
proteins, subsequently leading the recruitment and activa-
tion of the RHIM domain containing RIPK3 [2–7]. In the
necrosome complex, RIPK1 and RIPK3 are activated by
autophosphorylation and the recruited MLKL is subse-
quently phosphorylated by RIPK3, resulting in MLKL oli-
gomerisation through the interaction of its coiled-coil
domains (CCD) [8–10]. Oligomerised MLKL is translo-
cated onto the plasma membrane, consequently executing
necroptosis via plasma membrane permeabilization and
regulation of ion channels [8, 9, 11–13].
Checkpoints for executing necroptosis have been exten-
sively studied due to the importance of necroptosis in many
inflammatory, degenerative and infectious diseases [14]. In
general, RIPK1 as a scaffold promotes cell survival sig-
nalling while its kinase activity is implicated in apoptotic
and necroptotic cell death. Induction of RIPK1 kinase
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activity-mediated cell death is tightly controlled by several
checkpoints at different levels. RIPK1 ubiquitination by
cIAPs or the linear ubiquitin chain assembly complex is an
early checkpoint, which stabilizes complex I formation
leading to NF-κB and MAPK mediated gene induction and
survival signalling, thereby resulting in the inhibition of
complex II formation. Indeed, RIPK1 phosphorylation by
IKKα/β, TAK1, MK2, or TBK1 upon TNF stimulation
constitutes the second level of checkpoints determining cell
fate, which prevents the formation of complex II [15–23]. In
addition to RIPK1 modification, RIPK3 posttranslational
modifications are crucial events in necroptosis. CHIP and
Pellino 1 ubiquitinate and degrade RIPK3 protein levels
in an ubiquitin-mediated lysosome- and proteasome-
dependent manner, suppressing necroptosis [24, 25]. A20
removes RIPK3 ubiquitination, which restricts necrosome
complex formation [26]. TNF receptor-associated factor
2 (TRAF2) is also an inhibitor of necrosome complex
formation. TRAF2 constitutively binds to MLKL under
normal conditions and suppresses the interaction between
RIPK3 and MLKL in necroptotic stimulation [27].
Recently, the addition of O-linked β-N-acetylglucosamine
on T467 of RIPK3 inhibits RIPK1/RIPK3 necrosome for-
mation [28]. All these necroptosis regulatory mechanisms
involve the modulation of necrosome complex formation
itself. However, the regulatory mechanism of the post-
necrosome step is yet to be elucidated.
Beclin 1 is a core protein of the autophagy process,
containing protein-binding domains such as BCL2
homology (BH)-3 domain, coiled-coil domain (CCD), and
an evolutionarily conserved domain (ECD) [29, 30].
PIK3C3/Vps34 and Vps15 form a complex with Beclin 1
during autophagy, which subsequently generates PtdIns-
3P (phosphatidylinositol 3-phosphate), thus initiating
phagophore nucleation [30]. While Beclin 1 is a key
component of the autophagic process, it is also involved in
various other pathways, including the cell death process.
Under apoptotic conditions, active caspases cleave Beclin
1 to N- and C-terminal fragments, thus abrogating its
autophagic function [31, 32]. Moreover, the fragmented N-
terminus of Beclin 1 moves to the mitochondria membrane
to accelerate mitochondria membrane permeabilization
and apoptosis [31, 32]. Recently, Song et al. demonstrated
the autophagy-independent role of Beclin 1 in ferroptosis
[33]. AMP-activated protein kinase-mediated phosphor-
ylation of Beclin 1 induces interaction between Beclin 1
and SLC7A11, which suppresses the function of system
Xc
−, thereby inhibiting ferroptosis [33].
Here, we demonstrated that Beclin 1 is integrated into the
necrosome complex by interacting with the phosphorylated
form of MLKL. Beclin 1 binds to CCD of MLKL in
necroptosis process, which prevents MLKL oligomerisation
and the perforation of the plasma membrane, thus preventing
necroptosis. Physiologically, the conditional knockout of
Beclin 1 in bone marrow-derived macrophages (BMDM)
elevated cell death with the increase of MLKL oligomerisa-
tion compared to the control. Overall, these data suggest
that Beclin 1 functions as a negative regulator in the post-




Becn1 conditional knockout mice were obtained from the
European Mouse Mutant Cell Repository. LyzMCre mice
were obtained from M.-S. Lee (Yonsei University) [34].
Becn1 conditional knockout mice containing knockout first
allele were crossed with actin-flippase transgenic mice to
obtain Becn1floxed allele. Becn1floxed mice were crossed
with LyzMCre mice to produce macrophage-specific Becn1
knockout mice. Becn1 conditional knockout and LyzMCre
mice were genotyped via PCR using following primers:
Becn1 F 5′-TTGTACCGTGATTTAGGGCGTTTGC-3′, R
5′-CTCCCAAGTGCTGGGATTAAAGACG-3′; LyzMCre
F 5′-GGTCGATGCAACGAGTGATGAGGT-3′, R 5′-CA
GCATTGCTGTCACTTGGTCGTG-3′. The Institutional
Animal Care and Use Committees of the Laboratory Animal
Research Center at Yonsei University approved all the
experiments (IACUC-A-201811-822-01). Mice analyses
were not randomized. The investigators were not blinded to
allocation during experiments and outcome assessment.
Cell culture, plasmids, and transfection
HT-29 (human colorectal carcinoma; HTB-38; ATCC,
Manassas, VA, USA), TC-1 (mouse lung cancer cell line;
CRL-2785; ATCC), and Molm-13 (acute myeloid leuke-
mia; ATCC) cells were maintained in Roswell Park Mem-
orial Institute (RPMI; HyClone, Chicago, IL, USA) in 5%
CO2 at 37 °C. 293T (human embryonic kidney; CRL-3216;
ATCC), L929 (mouse fibrosarcoma; CRL-6364; ATCC),
and BMDM (mouse bone marrow-derived macrophage)
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; HyClone) in 5% CO2 at 37 °C. All media were
supplemented with 10% fetal bovine serum (HyClone) and
1% penicillin/streptomycin (Invitrogen, Carlsbad, CA,
USA). Hank’s Balanced Salt Solution (HBSS) (Thermo
Fisher Scientific, Waltham, MA, USA) was used to induce
autophagic conditions by preincubation for 2 h in HT-29,
TC-1, and L929 cells. All cells were tested mycoplasma
contamination using e-Myco™ plus Mycoplasma PCR
Detection Kit (#25237; Intron, Seongnam, Gyeonggi,
South Korea).
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The RIPK1 and RIPK3 constructs (pcDNA3-FLAG–
RIPK1 or RIPK3, pcDNA3-HA-RIPK1 or RIPK3) have
been described previously [24]. pcDNA3-FLAG-MLKL
mutants (T357E/S358D, 1–178, 179–471, Δ1–84,
Δ139–180) were generated using site-directed mutagenesis
and PCR, respectively. The Beclin 1 construct was provided
by HWL (Yonsei University) and subcloned into the
pcDNA3-HA, pcDNA3-FLAG, pMSCVpuro-FLAG, and
pMSCVhygro vectors using PCR. The pcDNA3-HA-Beclin
1 mutants (1–140, 141–277, 1–244, 141–450, 245–450,
Δ141–244 (ΔCCD)) and the pMSCVpuro-FLAG-Beclin
1 mutant (Δ141–244 (ΔCCD)) were generated using
PCR. pMSCVpuro-FLAG-Beclin 1 WT, ΔCCD, and
pMSCVhygro-FLAG-Beclin 1 resistant to BECN1 shRNA
or siRNA were generated using site-directed mutagenesis
with the following primers: F 5′-TCAGAGATACCG
TCTAGTTCCTTACGGA-3′, R 5′-TCCGTAAGGAAC
TAGACGGTATCTCTGA-3′. We obtained and engineered
pMSCVpuro-FLAG and pMSCVhygro-FLAG vectors from
Addgene (#53178, #75083).
pLKO.1 puro-shBECN1 and pLKO.1 hygro-shRIPK3
were generated using oligo annealing and cloning into an












GCTGGTT-3′. shMLKL (TRCN0000196317) was purchased
from Sigma-Aldrich.
For transfection, the plasmids were incubated with poly-
ethyleneimine (PEI) (Sigma-Aldrich) in serum-free media
for 20min, and then added to 293T cells. After incubating for
24 h, the cells were harvested and analysed.
Generation and validation of BECN1 knockout and
knockdown cell lines
LentiCRISPRv2 vector was obtained from Addgene
(Addgene plasmid #52961; Cambridge, MA, USA). As
suggested by the CRISPOR online program (http://crispor.
tefor.net), single-guide RNA-targeting exon 2 or 3 of the
human BECN1 gene (KO#1; 5′-CACCGCCTGGACC
GTGTCACCATCC-3′ or KO#2 and #3; 5′-CACCGCAG
GAGGAAGAGACTAACTC-3′) was cloned into lenti-
CRISPRv2 vector using GeCKO’s cloning protocol.
293T cells were transfected with lentiCRISPRv2-sgBECN1
vectors using packaging plasmids for the production of
lentivirus. HT-29 cells were then infected with the lentivirus
and selected using 1 μg/mL puromycin treatment for 7 days.
After puromycin selection, single-colony selection was
performed in order to identify Beclin 1 complete knockout
cells, verified by immunoblotting.
To establish a cell line expressing shRNA against Beclin
1, RIPK3, and MLKL, 293T cells were transfected with
pLKO.1 puro-shGFP, pLKO.1 puro-shBECN1#5, pLKO.1
puro-shBECN1#7, pLKO.1 puro-shMLKL, and pLKO.1
hygro-shRIPK3 using packaging plasmids to produce a len-
tivirus. HT-29 and Molm-13 cells were infected with the
lentivirus containing shGFP, shBECN1#5, #7, and shRIPK3
and stably transfected cells were selected by treatment with 1
μg/mL puromycin or 400 μg/mL hygromycin for 7 days. To
establish a cell line overexpressing shRNA-resistant Beclin 1,
293T cells were transfected with pMSCVpuro-FLAG-Beclin
1 or pMSCVhygro-FLAG-Beclin 1 using packaging plas-
mids for the production of a retrovirus. HT-29 cells were
infected with the retrovirus and stably transfected cells were
selected by treatment with 1 μg/mL puromycin or 400 μg/mL
hygromycin for 7 days.
siRNA and transfection
The ON-TARGET plus SMARTpool siRNAs for human
BECN1 pool (L-010552-00), BECN1 #5 (J-010552-05),
BECN1 #7 (J-010552-07), ATG7 pool (L-020112-00),
VPS34 pool (L-005250-00) and mouse Becn1 pool (L-
055895-00), Becn1 #7 (J-055895-07), Becn1 #8 (J-055895-
08), Atg7 pool (L-049953-00), Vps34 pool (L-063416-00)
were purchased from Dharmacon (Dharmacon, Lafayette,
CO, USA). Non-targeting pool (siNT, D-001810-10,
Dharmacon) was used as a control.
TC-1 and L929 cells were transfected with 10 or 20 nM
siRNAs using Lipofectamine RNAiMax (Invitrogen) for 48
h. Dharmafect 1 (Dharmacon) was used for HT-29 cell
transfection. siRNA transfection was performed according
to the manufacturer’s instructions.
Chemicals and cell death stimulation
BV6 (S7597), Birinapant (S7015), and Z-VAD-FMK
(S7023) were purchased from Selleck Chemicals (Hous-
ton, TX, USA). Human TNFα (210-TA-020; R&D Sys-
tems, Minneapolis, MN, USA), mouse TNFα (14-8321-62;
eBioscience, San Diego, CA, USA), emricasan (254750-02-
2; Cayman Chemical, Ann Arbor, MI, USA), GSK’963
(AOB9775; Aobious, Gloucester, MA, USA), GSK’872
(530389, Calbiochem, San Diego, CA, USA), necrostatin-1
(BML-AP309; Enzo Life Sciences, New York, NY, USA),
and necrosulphonamide (480073; Calbiochem, San Diego,
CA, USA), and anti-TNFα antibody (MAB610, R&D
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Systems) were purchased from the indicated companies.
Necroptotic cell deaths were induced via treatment with
following combinations of chemicals: HT-29 hTNFα
(30 ng/mL), BV6 (1 µM) or birinapant (1 µM), and Z-VAD-
FMK (30 µM); L929 mTNFα (5 ng/mL) and Z-VAD-FMK
(10 µM); TC-1 mTNFα (10 ng/mL), BV6 (1 µM), and Z-
VAD-FMK (20 µM); primary BMDM mTNFα (20 ng/mL),
BV6 (1 µM), and Z-VAD-FMK (20 µM); Molm-13 bir-
inapant (0.05 µM), and Z-VAD-FMK (20 µM) or emricasan
(1 µM).
Cell viability analysis and flow cytometry
To determine cell viability, treated cells were incubated
with Cell Titer-Glo for 20 min at room temperature (RT),
before being analysed using a luminometer (Cell Titer-Glo
Luminescent Cell Viability Assay kit, G7571, Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. Cell loss was calculated using the following
formula: cell loss= 100 – cell viability. For Annexin V and
7-AAD double staining, treated cells were harvested and
washed with PBS, and then followed by incubation with
Annexin V-FITC (556547; BD Biosciences) and 7-AAD
(00-6993-50, eBioscience)in Annexin V binding buffer
(51-66121E, BD Biosciences, Franklin Lakes, NJ, USA) for
15 min. For propidium iodide (PI) single staining, treated
cells were harvested and washed with PBS, followed by
incubation with PI (P4170; Sigma-Aldrich, St. Louis, MO,
USA) for 15 min. Dead cells were determined as the PI-
positive population. Stained cells were analysed using flow
cytometry (BD accuri C6, BD Biosciences). Data were
analysed using BD ACCURI C6 PLUS software (BD
Biosciences). All cell viability analyses were biologically
triplicated and presented as mean ± standard deviation.
Immunofluorescence microscopy
For immunofluorescence staining, HT-29 cells were cul-
tured in 12-well plates with coverslips. After treatment with
necroptosis stimuli for the indicated times, the cells were
fixed with 4% paraformaldehyde for 30 min at RT. Anti-p-
MLKL (S358) antibody (ab187091; Abcam, Cambridge,
United Kingdom) (1:50) and anti-Beclin 1 antibody (sc-
48341; Santa Cruz Biotechnology, Dallas, TX, USA) (1:25)
were added to each sample in immunofluorescence blocking
buffer (PBS with 3% BSA, 1% saponin, and 1% Triton X-
100), and then incubated at 4 °C overnight. Each sample
was washed with PBS three times. Alexa Fluor 488 anti-
mice (A-11029; Thermo Fisher Scientific) and Alexa
Fluor 594 anti-rabbit IgG conjugated antibodies (A-11032;
Thermo Fisher Scientific) were added to each sample in
immunofluorescence blocking buffer (PBS with 3% BSA,
1% saponin, and 1% Triton X-100), and then incubated at
RT for 1 h. Nucleus was stained with DAPI for 5 min and
analysed by LSM 700 (Carl Zeiss, Oberkochen, Germany).
Immunoprecipitation and immunoblotting
Cells were lysed with lysis buffer containing 50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, 1 mM
EDTA, and a protease inhibitor cocktail. Cell lysates were
immunoprecipitated by incubating with the indicated
antibodies for 2 h, followed by incubation with protein G
Sepharose (GE Healthcare, Chicago, IL, USA) for 2 h.
Next, samples were eluted in sample buffer and boiled for
5 min. For immunoprecipitation, anti-Beclin 1 (sc-48341;
Santa Cruz Biotechnology), caspase-8 (sc-6136; Santa
Cruz Biotechnology), FADD (sc-6036; Santa Cruz Bio-
technology), HA (sc-7392; Santa Cruz Biotechnology),
and FLAG (F3165; Sigma-Aldrich) antibodies were used.
Normal mouse IgG (sc-2025) and goat IgG (sc2028)
purchased from Santa Cruz Biotechnology were used as
controls.
For necrosome complex formation analysis, cells were
treated with TNFα and BV6 or birinapant in the presence of
Z-VAD-FMK for the indicated times. Cells were lysed in
death inducing signalling complex immunoprecipitation
buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1% Triton X-100, 10% glycerol, and 1 mM EDTA with a
proteasome inhibitor cocktail. Complexes were purified by
immunoprecipitation using anti-caspase-8 (sc-6136; Santa
Cruz Biotechnology) and FADD (sc-6036; Santa Cruz
Biotechnology) antibodies.
The following antibodies were used for immunoblotting:
Beclin 1 (1:1000; sc-11427; Santa Cruz Biotechnology and
1:2000; 3738S; Cell Signaling Technology), ATG7 (1:500;
#2631; Cell Signaling Technology, Danvers, MA, USA),
human caspase-8 (1:1000; #9746, Cell Signaling Technol-
ogy), mouse caspase-8 (1:1000; ALX-804-447; Enzo life
Science), hFADD (1:500; 610400; BD Bioscience),
mFADD (1:1000; 05-486; Merck Millipore, Burlington,
MA, USA), RIPK1 (1:1000; #610459; BD Bioscience),
hRIPK3 (1:2000; 13526; Cell Signaling Technology),
mRIPK3 (1:2000; NBP1-77299; Novus Biologicals, Cen-
tennial, Co, USA), p-hRIPK3 (S227) (1:2000; ab209384;
Abcam), hMLKL (1:2000; GTX107538; GeneTex, Irvine,
CA, USA), mMLKL (1:2000; AP14272b; Abgent, San
Diego, CA, USA), p-hMLKL (S358) (1:2000; ab187091;
Abcam), p-mMLKL (S345) (1:2000; ab196436; Abcam),
VPS34 (1:1000; #4263; Cell Signaling Technology), Rab5
(1:500; sc-46692; Santa Cruz Biotechnology), IκBα
(1:1000; #4814; Cell Signaling Technology), HA (1:5000;
11867431001; Roche, Basel, Switzerland), FLAG (1:3000;
F3165, F7425; Sigma-Aldrich), and β-actin (1:5000;
A5316; Sigma-Aldrich). The antibodies were purchased
from the indicated companies.
3068 J. Seo et al.
Gel filtration chromatography analysis
HT-29 cells stably expressing indicated shRNAs treated
with hTNFα (30 ng/mL), BV6 (1 µM), and Z-VAD-FMK
(30 µM) for the indicated times. Cells were harvested in
seven 100 mm culture dishes and lysed with 2.5 mL of lysis
buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
0.5% Triton X-100, and 1 mM EDTA. The lysates were
injected into AKTA Prime Plus and separated using a
HiLoad 16/600 Superdex 200 column at a flow rate of 0.4
ml/min (GE Healthcare). Fractions of 2 mL were collected
from 42 to 102 mL, and samples were analysed by western
blotting using the indicated antibodies. Molecular weight
markers were determined using gel filtration calibration kits
(GE Healthcare).
Triton X-114 phase partitioning
Triton X-114 phase partitioning was performed using the
multiple washing method. Briefly, cells were resuspended
in aqueous 2% (w/v) Triton X-114 containing 10 mM Tris-
HCl (pH 7.5) and 150 mM NaCl. The suspension was
incubated on ice for 30 min with frequent vortexing, and
then centrifuged at 10,000 g at 4 °C for 20 min to sediment
the pellet fraction (PF). The supernatant was collected and
incubated for 15 min at 37 °C to achieve phase partitioning.
The mixture was centrifuged at 5000 g at 25°C for 30 min,
and the upper aqueous phase (AP) and lower detergent
phase (DP) were carefully collected. The AP was further
purified by adjusting the Triton X-114 concentration to 2%
(w/v) and repeating the phase partitioning, as above.
Similarly, the DP was further purified by adding an equal
volume of aqueous 0.06% (w/v) Triton X-114 and repeating
the phase partitioning process.
MLKL oligomerisation
Non-reducing samples were prepared by lysing cells with
sample buffer containing 100 nM Tris-HCl, 4% SDS, 20%
glycerol, 20 mM EDTA, and bromophenol blue without
β-mercaptoethanol. For reducing samples, cells were lysed
with sample buffer containing 100 nM Tris-HCl, 4% SDS,
20% glycerol, 20 mM EDTA, bromophenol blue, and 200
mM β-mercaptoethanol. Both non-reducing and reducing
samples were boiled for 10 min, and then analysed via SDS-
PAGE.
Preparation of L929 conditioned medium
L929 cells were plated 5 × 105 cells in 150 T flask con-
taining 50 mL of 10% fetal bovine serum-supplemented
DMEM medium, and then incubated in 5% CO2 at 37 °C
for one week. The supernatant was collected and filtered
through 0.45 µm filter and stored at −70 °C.
Preparation of murine bone marrow-derived
macrophages (BMDM)
Bone marrow cells were obtained from 9-week-old gen-
otyped C57BL/6 mice. After euthanasia using CO2, the
hind legs were extracted by surgery. The femur was
separated from the tibia by cutting at the knee joint, and
the bone marrow cells in the hind legs were extracted by
flushing using a syringe containing serum-free media
several times into DMEM medium containing 10% fetal
bovine serum. Extracted cells were filtered through a 40
μm nylon cell strainer (SPL, Pocheon, Gyeonggi, South
Korea) to remove any debris. The extracted cells were
then collected via centrifugation. The supernatants were
discarded and the pellets were resuspended in media
before being transferred into a non-coating cell culture
dish. To remove fibroblast contamination, cells were
incubated in 5% CO2 at 37 °C for 4 h. Cells floating in the
supernatant were transferred into new non-coating culture
dishes, and then added L929 conditioned medium up to
10% for one week. Differentiated BMDM cells were sub-
cultured for further analysis.
Xenograft study
In total, 5 × 105 Molm-13 cells were prepared for each
mouse and resuspended in 50 μL of PBS. Cells were mixed
with 50 μL of Matrigel matrix (354234, BD Sciences). The
mixtures of cells and matrigels were subcutaneously
injected in the flank of 6-week-old female Balb/c nude
mice (Narabiotech, Seoul, Korea). After one week, mice
with xenograft tumours were inoculated with vehicle or
birinapant (2 mg/kg) plus emricasan (1 mg/kg) by i.p.
injection in every two days. Tumour growth was measured
as described previously [35]. After 18 days from tumour
inoculation, mice were sacrificed, and tumour volumes and
masses were determined as described previously [35]. We
analysed six mice for each group. Animal experiments
were approved by the Institutional Animal Care and Use
Committee of the Laboratory Animal Research at Yonsei
University (IACUC-A-201905-916-01). Xenograft ana-
lyses were not randomized. The investigators were not
blinded to allocation during experiments and outcome
assessments.
Statistical analysis
Statistical significance was assessed using Student’s t test in
GraphPad Prism software (Ver. 5.01; La Jolla, CA, USA).
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Results
Beclin 1 protects cells from necroptosis in an
autophagy-independent manner
Beclin 1 is a modulator of the apoptosis pathway [31]. To
further identify whether Beclin 1 is involved in TNFα-
induced necroptosis pathway, HT-29, TC-1, and L929 cells
were transfected with Beclin 1 siRNAs followed by treat-
ment with TNFα, Smac mimetic (BV6), and Z-VAD-FMK,
a pan-caspase inhibitor (TBZ). Interestingly, Beclin 1
depletion sensitised all three cell lines to TNFα-induced
necroptosis (Fig. 1a–c and Supplementary Fig. 1a–c).
However, treatment with necrostatin-1, a RIPK1 kinase
inhibitor, blocked the necroptotic cell death caused by TBZ
even in the ablated state of Beclin 1, suggesting that Beclin
1 has a protective role in RIPK1-dependent necroptosis
(Fig. 1a–c and Supplementary Fig. 1a–c). Since Beclin 1 is
a main component of the autophagy process, we further
confirmed the effect of autophagy in necroptosis regulation.
As previously reported, cells starved with HBSS incubation
displayed resistance to TNFα-induced necroptosis
(Fig. 1d–f and Supplementary Fig. 1d–f) [36]. The deple-
tion of ATG7, VPS34, and Beclin 1, which are key com-
ponents of autophagy, reversed the inhibitory effect of
HBSS incubation in TNFα-induced necroptosis, indicating
that autophagy might exhibit a negative function on
necroptosis (Fig. 1d–f and Supplementary Fig. 1d–f). It is
Fig. 1 Beclin 1-depleted cells are sensitised to necroptosis in an
autophagy-independent manner. a HT-29 cells depleted of Beclin 1
by the indicated siRNAs were treated with 30 ng/mL TNFα, 1 μM
BV6, and 30 μM Z-VAD-FMK (TBZ) in the presence or absence of
45 μM Nec-1 for 4 h. b TC-1 cells depleted of Beclin 1 by indicated
siRNAs were treated with 10 ng/mL TNFα, 1 μM BV6, and 20 μM Z-
VAD-FMK (TBZ) in the presence or absence of Nec-1 for 3 h. c L929
cells depleted of Beclin 1 by the indicated siRNAs were treated with
5 ng/mL TNFα and 10 μM Z-VAD-FMK (TZ) in the presence or
absence of Nec-1 for 3 h. a–c Knockdown efficiencies were deter-
mined by western blotting. After inducing necroptosis, cells were
stained with annexin V-FITC and 7-AAD, before analysing by flow
cytometry. d HT-29, e TC-1, and f L929 cells depleted of autophagy
factors by the indicated siRNAs were treated with TBZ or TZ under
either normal conditions or autophagic conditions induced by pre-
incubation with HBSS media. After treatment for inducing necropto-
sis, cells were stained with annexin V-FITC and 7-AAD, before being
analysed by flow cytometry. Data are the mean ± standard deviation
(S.D.), n= 3, with ns non-significance, *P < 0.05, **P < 0.01, and
***P < 0.001 at each point compared to indicated graph with the two-
sided Student’s t test (a–f).
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worth noting that ATG7 and VPS34 depletions did not
affect TNFα-induced necroptosis under normal conditions,
whereas Beclin 1 depletion promoted TNFα-induced
necroptosis in normal as well as HBSS medium
(Fig. 1d–f and Supplementary Fig. 1d–f). Collectively,
these results indicate that Beclin 1 is involved in necroptosis
in an autophagy-independent manner.
Beclin 1 incorporated into the necrosome complex
in an MLKL-dependent manner suppresses MLKL
oligomerisation
Maintaining the levels of proteins involved in necroptosis is
necessary for modulating necroptosis. However, under
Beclin 1-depleted conditions, no obvious changes were
observed in the protein levels of necroptotic factors in HT-
29, TC-1, or L929 cells (Supplementary Fig. 2a). There was
also no change in IκBα degradation caused by TNFα
treatment under Beclin 1 ablation (Supplementary Fig. 2b).
Moreover, Beclin 1 ablation had no effect on the formation
of the RIPK1/RIPK3/MLKL necrosome complex (Fig. 2a).
To determine whether autophagy factors are incorporated in
the complex, the presence of autophagy factors in the
necrosome complex was investigated. The results showed
that in HT-29 and TC-1 cells, only Beclin 1, and not ATG7
and VPS34, was recruited to the necrosome complex in
response to TBZ (Fig. 2a–c). Notably, the incorporation of
Beclin 1 in the complex occurred at 2 and 1.5 h in HT-29
and TC-1 cells, respectively, when the complete RIPK1/
RIPK3/MLKL complex was formed, suggesting that Beclin
1 could be involved in the later stages of the necroptotic
process (Fig. 2b, c). We have further explored the integra-
tion of Beclin 1 into the necrosome complex through
gel filtration analysis using HT-29 cells. As previously
reported, the necroptotic stimulus by TBZ triggered the
translocation of RIPK1, RIPK3, and MLKL into a large
Fig. 2 Beclin 1 is incorporated into the necrosome complex. a HT-
29 cells were transfected with the indicated siRNAs for 48 h, and then
treated with TBZ for the indicated times. After treatment, the cells
were lysed with lysis buffer and incubated with the anti-caspase-8
antibody. Samples were precipitated by incubating with protein G
agarose, followed by immunoblotting analysis using the indicated
antibodies. HT-29 (b) and TC-1 cells (c) were treated with TBZ for the
indicated times. After treatment, the cells were lysed with lysis buffer
and then immunoprecipitated using the anti-caspase-8 antibody (b) or
anti-FADD antibody (c). The protein levels were determined by
immunoblotting using the indicated antibodies. d Control and TBZ
treated-HT-29 cells were lysed using lysis buffer and then fractionated
according to their molecular size by gel filtration chromatography. The
samples were analysed by immunoblotting.
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multi-protein complex (Fig. 2d). While VPS34 and ATG7
did not translocate to the macromolecular fractions in
response to TBZ, Beclin 1 was translocated upon treatment
with TBZ (Fig. 2d). The next question was whether Beclin 1
could affect the macromolecular translocation of necroptosis
factors under necroptosis stimulation. When Beclin 1 was
depleted, there was no noticeable change in the translocation
of RIPK1, RIPK3, and MLKL to their macromolecular
fractions upon TBZ treatment (Fig. 3a). Interestingly, when
MLKL was depleted using MLKL-specific shRNAs, Beclin 1
translocation into high molecular weight fractions was
strongly reduced (Fig. 3a). These observations were further
supported when GSK’872, an inhibitor of RIPK3, was used
upon the cells with necroptotic stimuli, which resulted in a
significant decrease of MLKL and Beclin 1 binding to the
necrosome complex, suggesting that the incorporation of
phosphorylated MLKL into the necrosome complex may be
required for the recruitment of Beclin 1 into the complexes
(Fig. 3b).
Beclin 1 had no clear effect on the levels of necrosome
complex formation and required MLKL to be incorporated
into the complex. Hence, we investigated the effect of
Beclin 1 on the status of MLKL phosphorylation or oligo-
merisation. Beclin 1 depletion promoted MLKL oligomer-
isation without affecting MLKL phosphorylation in HT-29
and TC-1 cells (Fig. 3c). It is well demonstrated previously
that membrane localisation of MLKL follows MLKL oli-
gomerisation [8, 9, 11–13, 37]. When the membrane
Fig. 3 Beclin 1 inhibits MLKL oligomerisation in the necrosome
complex. a HT-29 cells expressing shGFP, shBECN1, and shMLKL
were treated with TBZ. After treatment, the cells were lysed using lysis
buffer and then fractionated according to their molecular size by gel
filtration chromatography. The samples were analysed by immuno-
blotting. b HT-29 cells were treated with 30 ng/mL TNFα, 1 μM
Birinapant, and 30 μM Z-VAD-FMK (TBiriZ) in the presence or
absence of 2 μM GSK'872 for 5 h. After treatment, the cell lysates
were immunoprecipitated using anti-caspase-8 antibody and then
analysed by immunoblotting. c HT-29 and TC-1 cells were transfected
with the indicated siRNAs, and then treated with TBZ in the presence
or absence of Nec-1 for the indicated times. After treatment, the cell
lysates were lysed under non-reducing conditions to detect MLKL
oligomerisation or under reducing conditions and then analysed by
immunoblotting. d HT-29 cells were transfected with the indicated
siRNAs for 48 h and then treated with TBZ in the presence or absence
of Nec-1 for the indicated time points. After treatment, the cell lysates
were lysed using Triton X-114 buffer to divide them into detergent and
aqueous phases. Each lysate was analysed by immunoblotting.
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localisation of MLKL was analysed, there was an increased
of MLKL under Beclin 1-depleted conditions in HT-29
cells with necroptotic stimulus for more than 4 h (Fig. 3d).
Overall, these results suggest that Beclin 1 is recruited into
the necrosome complex in an MLKL-dependent manner
and subsequently restricts necroptosis via the suppression of
MLKL oligomerisation, which retards translocalisation into
the plasma membrane.
Beclin 1 is incorporated into the necrosome complex
via the interaction with phosphorylated MLKL
To find which necroptosis-related proteins interact with
Beclin 1, immunoprecipitation analyses were performed
(Fig. 4a, b). While the interaction between Beclin 1 and
RIPK3 is interesting, Beclin 1 was incorporated into the
necrosome complex in an MLKL-dependent manner.
Hence, we decided to investigate the interaction between
Beclin 1 and MLKL rather than RIPK3. As expected, the
interaction between endogenous Beclin 1 and MLKL was
enhanced upon necroptotic stimulus in HT-29 and TC-1
cells (Fig. 4c). Furthermore, when the interaction between
Beclin 1 and MLKL was analysed in the gel filtration
fractions from Fig. 2d using immunoprecipitation by Beclin
1 antibody, we only observed the interactions between the
two proteins in the fractions treated with TBZ but not in the
control fractions, indicating that Beclin 1 forms a complex
with MLKL in response to necroptotic stimulus (Fig. 4d).
Fig. 4 Phosphorylation of MLKL is required for the recruitment
of Beclin 1 into the necrosome complex. a, b 293T cells were
transfected with the indicated plasmids and then immunoprecipitated
using anti-FLAG antibody. The samples were analysed by immuno-
blotting using anti-FLAG and HA antibodies. c HT-29 and TC-1 cells
were treated with TBZ for the indicated times. After treatment, the cell
lysates were immunoprecipitated using anti-Beclin 1 antibody and then
analysed by immunoblotting. d HT-29 cells were treated with TBZ
and fractionated according to their molecular size. After fractionation
of the cell lysates, each fraction was immunoprecipitated using anti-
Beclin 1 antibody, followed by immunoblot analysis. e 293T cells
were transfected with the indicated plasmids. The cells were lysed
using a lysis buffer and then immunoprecipitated using anti-FLAG
antibody. The samples were analysed by immunoblotting. f HT-29
cells were treated with TBZ in the presence or absence of 100 nM
GSK’963 for 5 h. After treatment, the cells were fixed and stained
using anti-Beclin 1 and p-MLKL antibodies, and DAPI. The histogram
represents the subcellular integrity of Beclin 1 and p-MLKL in the
areas indicated by the red arrows. The boxed areas are shown at higher
magnification on the right. Scale bars= 20 μm.
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The phosphorylation of human MLKL at threonine 357
and serine 358 by RIPK3 leads to the conformational
change of MLKL from the CCD masked form to the CCD
unmasked form, which enables MLKL oligomerisation
(Fig. 7e) [38–40]. Enhancement of the interaction between
Beclin 1 and MLKL upon TBZ treatment led us to speculate
whether the phosphorylation of MLKL is required for
strong binding between the two proteins. As shown in
Fig. 4e, the phosphomimetic mutant of MLKL bound to
Beclin 1 more strongly than the MLKL wild type (Fig. 4e).
The interaction between the endogenous phosphorylated
MLKL and Beclin 1 was further confirmed by confocal
analysis. Interestingly, Beclin 1 moved to a specific locus in
the cytoplasm in response to the necroptotic stimulus of
TBZ, simultaneously co-localising with phosphorylated
MLKL as shown in the merged figure (Fig. 4f, arrowheads).
In particular, when the areas in which MLKL was aggre-
gated were treated with TBZ, they showed co-localisation
of MLKL and Beclin 1 (White arrowheads). The treatment
of GSK’963, a RIPK1 inhibitor, with TBZ completely
blocked the formation of the phosphorylation of MLKL as
detected by the disappearance of the red immuno-
fluorescence and the disperse distribution of the Beclin 1,
indicating that the co-localisation of Beclin 1 with MLKL
requires the formation of a necrosome complex (Fig. 4f).
These observations imply that Beclin 1 might be associated
at the site of MLKL complex formation plausibly restricting
the perforating complexes of MLKL. Collectively, these
results imply that Beclin 1 is recruited into the necrosome
complex via its interaction with the phosphorylated and thus
CCD unmasked forms of MLKL.
Ablation of Beclin 1 enhances the pore-formation of
oligomerised MLKL
While we detected the enhancement of oligomerisation of
MLKL and necroptotic cell death upon Beclin 1 knock-
down, it is still unclear whether the absence of Beclin 1
could promote the formation of phosphorylated MLKL
complexes observed in Fig. 4f. To more precisely assess the
role of Beclin 1 in this process, we prepared three Beclin 1
knockout HT-29 cell lines using the CRISPR/Cas9 system
and three Beclin 1 knockout BMDM from Beclin 1
macrophage-specific knockout mice (Fig. 5a, b and Sup-
plementary Fig. 3). As shown in Fig. 5c, d, all Beclin 1
knockout cell were sensitised to the necroptotic stimulus
(Fig. 5c, d and Supplementary Fig. 4a). The increased oli-
gomerisation of MLKL was also observed (Fig. 5e, f and
Supplementary Fig. 4b). When HT-29 WT or BECN1 KO#1
cells were treated with TBZ, we were able to observe the
dotted co-localisation of the endogenous Beclin 1 and
phosphorylated MLKL (Fig. 5g, BECN1, WT, arrowheads).
However, there was a great increase in the number and
intensities of the dotted complexes of MLKL in the BECN1
KO#1 cells compared with HT-29 WT cells (Fig. 5g,
square). The phosphorylated MLKL was no longer detected
under the treatment of GSK’963 indicating the dependency
of these processes on necroptosis (Fig. 5g). Next, we
wondered whether the increases of cell death and MLKL
oligomerisation in Beclin 1 knockout HT-29 cells are solely
dependent on the ablation of Beclin 1. We re-expressed
wild type Beclin 1 in Beclin 1 knockout HT-29 cells
(Supplementary Fig. 5a). The expression of wild type
Beclin 1 in Beclin 1 knockout HT-29 cells reduced TBZ-
induced cell death as well as MLKL oligomerisation, indi-
cating that the escalated necroptosis in Beclin 1 KO cells
could be due to the absence of Beclin 1 and not by other
factors (Supplementary Fig. 5b, c). Finally, in order to
further analyse the effects of Beclin 1’s ability to suppress
the formation of dotted complexes of phosphorylated
MLKL, we constructed an HT-29 cell line that was depleted
of Beclin 1 using lentivirus expressing BECN1 shRNA.
Subsequently, we overexpressed shRNA-resistant Beclin 1
using retroviral system. Upon knockdown of Beclin 1, we
observed the increased necroptotic cell death and dotted
complexes of phosphorylated MLKL, while these were
reversed by Beclin 1 overexpression (Supplementary
Fig. 5d–g). Overall these data indicate that the incorporation
of Beclin 1 hampers the formation of the functional com-
plexes of phosphorylated MLKL perforating the plasma
membrane and thus suppresses necroptosis.
Coiled-coil domain of Beclin 1 is responsible for
Beclin 1-mediated necroptosis regulation
Since Beclin 1 functions as a negative integral component
of necrosome complexes, the domain mapping analyses
between Beclin 1 and MLKL were carried out. Wild type
and fragments of the CCD of Beclin 1 were capable of
interacting with MLKL (Supplementary Fig. 6a, b). The N-
terminal fragment of MLKL was also found to be important
for binding to Beclin 1 (Supplementary Fig. 6c, d). We next
analysed each CCD of MLKL by producing two deletion
mutants, Δ1–84 and Δ139-180, which are known to play an
essential role in maintaining MLKL structural integrity [9].
Both MLKL deletion mutants bound to Beclin 1, suggesting
that the two CCDs of MLKL may redundantly interact with
Beclin 1’s CCD (Supplementary Fig. 6e).
We further tested the importance of CCD of Beclin 1 in
preventing MLKL oligomerisation by expressing wild type
Beclin 1 or its deletion mutant, ΔCCD, having resistance to
Beclin 1 siRNA in HT-29 cells depleted of Beclin 1 siRNA
(Fig. 6a). When the cells depleted of Beclin 1 were exposed
to necroptotic stimuli, wild type Beclin 1 expression was
able to suppress TBZ-induced necroptosis, while ΔCCD
expression could not (Fig. 6b, c). Accordingly, the
3074 J. Seo et al.
enhanced oligomerisation of MLKL in HT-29 cells depleted
of Beclin 1 was also diminished by the expression of the
wild type Beclin 1, while ΔCCD failed to repress MLKL
oligomerisation (Fig. 6d). To further characterize the nature
of the interaction between Beclin 1 and MLKL CCDs,
necrosulfonamide (NSA), an MLKL inhibitor, was
employed. NSA is known to bind to cys86 in the CCD of
MLKL, which abrogates MLKL oligomerisation and thus
represses necroptosis [11, 41]. When NSA was employed to
treat cells under necroptotic stimuli, we observed that the
formation of MLKL oligomerisation was completely
blocked, as previously reported (Fig. 7a) [11]. Unexpect-
edly, treatment of NSA restricted the incorporation of
Beclin 1 into the necrosome complex and the interaction
between Beclin 1 and MLKL, indicating that NSA might
block the incorporation of Beclin 1 into the necrosome
complex (Fig. 7b, c). Corroborating these results, NSA was
found to suppress the co-localisation of Beclin 1 and
phosphorylated MLKL in the cytoplasmic area upon treat-
ment with TBZ (Fig. 7d).
Taken together, these results indicate that the CCD of
Beclin 1 is required for the association with CCD of MLKL,
Fig. 5 Beclin 1 knockout promotes necroptosis. a Beclin 1 protein
levels were determined by immunoblotting in Beclin 1 wild type (WT)
or knockout (KO) HT-29 cells. b Beclin 1 protein was detected by
immunoblotting in Becn1F/F and Becn1LyzMKO BMDM. c, e Beclin 1
WT or KO HT-29 cells were treated with TBZ in the presence or
absence of GSK'963 (TBZG) for 4 h. After treatment, the cells were
stained with annexin V-FITC and 7-AAD for 20 min, and then ana-
lysed via flow cytometry (c). To analyse MLKL oligomerisation, the
cells were lysed under non-reducing conditions for MLKL oligomer-
isation or under reducing conditions, and then analysed by immuno-
blotting (e). Flow cytometry data are the means ± S.D., n= 3, with
**P < 0.01 and ***P < 0.001 at each point compared to indicated
graph with the two-sided Student’s t test (c). d, f Becn1F/F and
Becn1LyzMKO BMDMs were treated with 20 ng/mL TNFα, 1 μM BV6,
and 20 μM Z-VAD-FMK (TBZ) in the presence or absence of 100 nM
GSK’963 (TBZG) for 2 h. After treatment, the cell loss was deter-
mined via cell titer-glo (d). The cell loss data are the means ± S.D.,
n= 3, with ***P < 0.001 at each point compared to indicated graph
with the two-sided Student’s t test (d). To analyse MLKL oligomer-
isation, the cells were lysed under non-reducing conditions for MLKL
oligomerisation or under reducing conditions, and then analysed by
immunoblotting (f). g Beclin 1 WT and KO HT-29 cells were treated
with TBZ in the absence or presence of GSK’963 for 5 h. After
treatment, the cells were fixed and stained with the anti-Beclin 1,
p-MLKL antibodies, and DAPI. The boxed areas are shown at higher
magnification to the below. Scale bars= 20 μm.
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which would prevent the oligomerisation of MLKL via its
own CCD. Moreover, NSA competes against Beclin 1 for
MLKL interaction, suggesting that the CCD of Beclin 1
might interact with the motif of MLKL CCD interacting
with NSA (Fig. 7e).
AML cells are sensitised to necroptosis in vitro and
in vivo after Beclin 1 depletion
The role of Beclin 1 as an anti-necroptotic factor prompted
us to further explore the effect of Beclin 1 depletion, as an
anti-tumour therapy. Molm-13, an acute myeloid leukaemia
(AML) cell line, expresses RIPK3 and is known to undergo
necroptosis [42–44]. The autocrine TNFα signalling in
Molm-13 cells has been shown to be sufficient to induce
necroptotic cell death, mediated by Smac mimetic and
caspase inhibitor; therefore, we used the combination of
Smac mimetic and caspase inhibitor for further necroptosis
stimulation in Molm-13 cells (Supplementary Fig. 7a) [43].
Beclin 1 depletion in Molm-13 cells, carried out using
two Beclin 1 shRNAs (shBECN1#5 and shBECN1#7),
enhanced Smac mimetic- and Z-VAD-FMK-induced
necroptosis (Fig. 8a and Supplementary Fig. 7b–f). The
progress of the necroptosis was suppressed by GSK’963
Fig. 6 Beclin 1 but not Beclin 1 ΔCCD prevents necroptosis by
suppressing MLKL oligomerisation. a–d HT-29 cells stably
expressing FLAG-siBECN1#5-resistant Beclin 1 wild type (WT), or
Beclin 1 CCD-truncated mutant (ΔCCD) were transfected with siNon
and siBECN1#5 for 48 h. a The protein levels were determined by
immunoblotting. b, c To analyse necroptotic population, the cells were
treated with TBZ in the presence or absence of GSK'963 (TBZG) for
4 h. After treatment, the cells were stained with annexin V-FITC and
7-AAD, followed by flow cytometry analysis. Data are expressed as
the mean ± S.D., n= 3, with *P < 0.05 and ns non-significance at each
point compared to the indicated graph with the two-sided Student’s t
test. d To analyse MLKL oligomerisation, the cells were treated with
TBZ in the presence or absence of GSK'963 (TBZG) for 4 h. After
treatment, the cell lysates were lysed under non-reducing conditions
for MLKL oligomerisation or under reducing conditions, and were
then analysed by immunoblotting.
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and RIPK3 depletion (Fig. 8a and Supplementary
Fig. 7b–h). In addition to Z-VAD-FMK, Beclin 1-depleted
Molm-13 cells were also sensitised after exposure to emri-
casan, another caspase inhibitor (Fig. 8b and Supplementary
Fig. 7b–f). As a result of necroptotic stimuli, an increase in
MLKL oligomerisation was observed in this cell line,
indicating that Beclin 1 also functions as an anti-necroptotic
factor by suppressing MLKL oligomerisation in the AML
cell line (Fig. 8c, d). To validate the anti-necroptotic role of
Beclin 1 in vivo, a skin xenograft analysis was performed.
The results showed that treatment with birinapant plus
emricasan in shGFP-expressing groups suppressed the
growth of tumour by up to 20%. While Beclin 1 depletion
alone did not have observable effects on tumour growth
compared to those of shGFP in the vehicle group, treatment
with birinapant and emricasan induced a 50.3% reduction in
the growth of the tumour (Fig. 8e–i). Furthermore, RIPK3
depletion reversed the effect of Beclin 1 depletion on
tumour growth, which was induced by treatment with
birinapant and emricasan, suggesting that depletion of
Beclin 1 might be accelerating the necroptotic processes in
the tumour model (Fig. 8e–i and Supplementary Fig. 7i).
Collectively, these results indicate that Beclin 1 down-
regulation renders the AML cells sensitive to necroptotic
cell death, implying that Beclin 1 can be used as a plausible
therapeutic target for necroptosis-induced anti-tumour
therapy.
Discussion
Necroptosis is a potent form of regulated cell death, which
could induce the uncontrolled systemic induction of
immune responses. Thus, several checkpoint regulators may
be necessary to block the uninhibited progress of necrop-
tosis. Recently, several proteins modulating necroptosis
have been reported [17–27]. These regulatory proteins are
limited in the pre-necrosome complex step, which consists
Fig. 7 NSA and Beclin 1 compete for CCD of MLKL. a HT-29 cells
were treated with TBZ in the presence or absence of GSK’963 or
NSA. After treatment, cell were lysed under non-reducing conditions
for MLKL oligomerisation or under reducing conditions, and then
analysed by immunoblotting. b HT-29 cells treated with TBZ in the
presence or absence of 5 μM NSA for 5 h. After treatment, the cell
lysates were immunoprecipitated using the anti-caspase-8 antibody,
and then analysed by immunoblotting. c HT-29 cells treated with TBZ
in the presence or absence of NSA were lysed and immunoprecipitated
using the anti-Beclin 1 antibody, followed by immunoblotting analy-
sis. d HT-29 cells treated with TBZ in the presence or absence of NSA
for 5 h were fixed and stained with the anti-Beclin 1, p-MLKL anti-
bodies, and DAPI. The histogram represents the subcellular integrity
of Beclin 1 and p-MLKL of the areas indicated by the red arrows.
The boxed areas are shown at higher magnification to the right.
Scale bars= 20 μm. e Scheme for the hypothetical model of interaction
between Beclin 1 and MLKL with necroptotic stimuli in the presence
or absence of NSA.
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of the process before the formation of the RIPK1/RIPK3
complex. By suppressing the early necroptotic phase, the
cells affected by cell death signals could avoid facing an
irreversible cell death process. However, the presence of
negative regulators for the late necroptotic phase involving
the post-necrosome complex could not be excluded to delay
the cell death process and alleviate its effects. In this study,
we demonstrated that Beclin 1 functions as a negative
regulator of necroptosis by its integration into the necro-
some complex of phosphorylated RIPK1/RIPK3/MLKL. As
such, Beclin 1 could be defined as a key regulator of the
post-necrosome complex. The incorporation of Beclin 1
into the necrosome complex is interesting in that the process
neither hinders the phosphorylation nor the complex for-
mation process of RIPK1, RIPK3, and MLKL. Beclin 1 was
found to be incorporated into the necrosome complex via
MLKL interaction and inhibited necroptosis via blocking
MLKL oligomerisation. The association between Beclin 1
and phosphorylated MLKL is further demonstrated via the
confocal analyses showing that, under necroptotic stimuli,
Beclin 1 and phosphorylated MLKL was co-localised in the
cytoplasmic area of cells. This association in the cells was
disrupted in the presence of NSA or GSK’872, an inhibitor
of MLKL or RIPK3, respectively, further demonstrating the
association of Beclin 1 with MLKL.
Incorporation of Beclin 1 is important to have a negative
effect on necroptosis. When MLKL is phosphorylated in
the pseudokinase domain by RIPK3, the intramolecular
interaction between CCDs and pseudokinase domain is
disrupted, leading to the formation of an extended
Fig. 8 Beclin 1 depletion in Molm-13 promotes necroptosis in vitro
and in vivo. Molm-13 cells expressing shGFP and shBECN1 #5 were
treated with 0.05 μM birinapant and 20 μM Z-VAD-FMK (Biri/Z) (a)
or 1 μM emricasan (Biri/Emri) (b) in the presence or absence of
100 nM GSK'963 for 10 h, and then stained with propidium iodide (PI)
for 15 min. After staining, the cell death was determined by flow
cytometry. The data are mean ± S.D., n= 3, with ***P < 0.001 at each
point compared to the indicated graph using a two-sided Student’s t
test. Molm-13 cells expressing indicated shRNAs were treated with
0.05 μM birinapant and 20 μM Z-VAD-FMK (Biri/Z) (c) or 1 μM
emricasan (Biri/Emri) (d) in the presence or absence of 100 nM
GSK'963 for 10 h. The cells were lysed under reducing conditions or
under non-reducing conditions for MLKL oligomerisation, and ana-
lysed by immunoblotting. e Scheme for the subcutaneous tumour
xenograft model. f–i 5 × 105 Molm-13 cells expressing indicated
shRNAs were subcutaneously injected in the flank of 6-week-old
female nude mice. After one week, the mice bearing tumours were
injected with birinapant (2 mg/kg) plus emricasan (1 mg/kg) as indi-
cated in (e) by i.p. injection for 2 weeks. Tumour growth (f), tumour-
bearing mice (g), resected tumours (h), tumour masses (i) are shown.
Data are means and individual data points from n= 6 mice, with *P <
0.05, **P < 0.01, ***P < 0.001, and n.s.= non-significance according
to the two-tailed Mann–Whitney test.
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conformation, producing an MLKL molecule with CCDs
prepared to form multiple complexes of MLKL
[8, 9, 11, 12, 38–41, 45, 46]. These MLKL complexes are
known to translocate to the edge of a cell, causing mem-
brane perforations and thus disruption of the plasma
membrane [8, 9, 12, 13, 37]. Noteworthy, the CCD of
Beclin 1 was found to interact with the CCDs of MLKL.
Beclin 1 devoid of CCD was unable to suppress necrop-
tosis when overexpressed, indicating that the CCD of
Beclin 1 is important for its interaction with MLKL.
Furthermore, NSA, a chemical which binds to the CCD
region of MLKL to prevent its oligomerisation, also
inhibited the binding of MLKL and Beclin 1 under
necroptosis. The competition of NSA and Beclin 1 for
MLKL CCDs indirectly indicates that Beclin 1 specifi-
cally binds to the MLKL CCD region. The binding of the
CCD of Beclin 1 to the exposed CCDs of phosphorylated
MLKL leads to the inhibition of MLKL multiplex for-
mation, thereby significantly hindering the necroptosis
process induced by MLKL oligomerisation (Fig. 7e). Of
note, TAM kinase was shown to promote necroptosis by
inducing phosphorylation at MLKL tyrosine 376 residue,
inducing oligomerisation of the pseudokinase domain of
MLKL and plasma membrane rupture [47]. Since Beclin 1
does not interact with the kinase domain of MLKL, fur-
ther studies are required to identify how Beclin 1 could
prevent MLKL oligomerisation possibly by affecting
TAM kinase-dependent MLKL oligomerisation.
While our study demonstrated the association between
Beclin 1 and MLKL and elucidated the mechanisms
involved in the necroptosis process, further questions
remain. Beclin 1 can function in both autophagy-dependent
and -independent pathways. As shown in Fig. 1, the inhi-
bition of necroptosis under conditions inducing autophagy
and the interruption of this process by the ablation of Beclin
1 suggests the involvement of the autophagy pathway in
necroptosis. This pathway and the role of Beclin 1 in this
process need to be studied further. Here, we showed that
Beclin 1 also functions in an autophagy-independent way
by targeting MLKL oligomerisation under non-autophagic
conditions. These observations, however, indicate the pos-
sibility of more intricate novel pathways, as Beclin 1 has
multiple binding partners with its diverse protein–protein-
binding domains, including BH3, CCD, and ECD (Sup-
plementary Fig. 6). Since many proteins are known to
regulate the function of Beclin 1 posttranslationally through
phosphorylation, ubiquitination, ISGylation, and acetyla-
tion, the next step would be to determine whether these
modulations of Beclin 1 affect the interaction between
Beclin 1 and MLKL, which could lead to the discovery of
unanticipated and novel pathways affecting necroptosis
[29, 30]. Finally, we analysed the anti-necroptotic effect of
Beclin 1 using a xenograft model system (Fig. 8). Beclin
1-depleted Molm-13 cells were sensitised to Smac
mimetic and caspase inhibitor-mediated necroptosis
in vitro and in vivo, which was recovered by RIPK3
inhibition. The anti-necroptotic effect of Beclin 1 in AML
cells appears to arise from the ability to suppress MLKL
oligomerisation, which in turn protects the AML cell from
necroptosis. However, further studies on the suitability of
Beclin 1 as an anti-tumour target would be required to
develop a novel therapeutic target in anti-tumour therapy
involving necroptosis.
In this study, we demonstrated that Beclin 1 is a new
negative member of the necrosome complex. Beclin 1
interacts with the CCD of MLKL during necroptosis and
consequently suppresses necroptosis by reducing MLKL
oligomerisation. The autophagy-independent function of
Beclin 1 in necroptosis provides an insight into the
molecular mechanism of cell death and has therapeutic
implications in necroptosis-related diseases and anti-
tumour therapies.
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